HOME >> BIOLOGY >> NEWS
Researchers identify enzyme essential for battle against bacteria in the intestine

St. Louis, Oct. 1, 1999 -- A paper in today's Science identifies an enzyme essential for the body's daily battle against bacteria in the intestine and possibly in other organs such as the lung and bladder. This work might one day help drug companies design more effective drugs to combat a myriad of diseases, including gingivitis, bladder infections and cystic fibrosis.

"This enzyme activates molecules called defensins, which people always thought were a key line of defense against bacteria. But no one has proven it until this paper," said senior author William C. Parks, Ph.D., associate professor of pediatrics and of cell biology and physiology at Washington University School of Medicine in St. Louis.

The enzyme, called matrilysin, belongs to a large family of enzymes called matrix metalloproteinases, or MMPs. Implicated in a surprising number of diseases, MMPs chew up proteins in the extracellular matrix, a supportive network surrounding cells.

When matrix-degrading metalloproteinases go overboard, they can cause disease. In osteoarthritis, for example, they are thought to break down cartilage in joints, making it painful and difficult for people to use their hands or walk. In cancer, tumor cells use the enzymes to tear down extracellular matrix, gaining passage into the bloodstream and spreading through the body.

MMPs also play important roles in healthy tissue. They often spur normal growth and healing, shaping embryos and remodeling skin in healing wounds.

The Science paper showed that matrilysin protects the epithelial lining of the intestine by regulating the activity of defensins. This might be a common role for this metalloproteinase in the many places where it is made.

Parks and lead author Carole L. Wilson, Ph.D., research assistant professor of pediatrics at Washington University School of Medicine, began studying matrilysin, which shows up in normal, uninjured
'"/>

Contact: Diane Duke Williams
duke@medicine.wustl.edu
314-286-0111
Washington University School of Medicine
1-Oct-1999


Page: 1 2 3

Related biology news :

1. Researchers determine genetic cause of Timothy syndrome
2. Researchers find color sensitive atomic switch in bacteria
3. Researchers identify protein promoting vascular tumor growth
4. Researchers devise potent new tools to curb ivory poaching
5. Researchers create nanotubes that change colors, form nanocarpet and kill bacteria
6. Researchers ID chlorophyll-regulating gene
7. Researchers develop fast track way to discover how cells are regulated
8. Researchers identify distinctive signature for metastatic prostate cancer
9. Researchers report new gene test for isolated cleft lip and palate
10. Researchers discover why mutant gene causes colon cancer
11. Researchers identify the genomes controlling elements

Post Your Comments:
(Date:10/17/2014)... Copenhagen have shown for the first time how bacteria ... patients, giving them the opportunity to get tremendous insights ... The study also discovered the bacterial growth in chronic ... or slowed down by the immune cells. The researchers ... helped "suffocate" the bacteria, forcing the bacteria to switch ...
(Date:10/16/2014)... on the human body. Battles are won, lost ... cancer, this stalemate—known as tumor dormancy—can last up ... phenomena that is poorly understood. , A ... Salvatore Torquato, a Professor of Chemistry at Princeton ... dormancy and the switch to a malignant state. ...
(Date:10/16/2014)... new synthesis of recent research findings to inform their ... two states. , The Ecology and Management of ... Synthesis of the Relevant Biophysical Science and Implications for ... the U.S. Forest Service,s Pacific Northwest Research Station, is ... a synthesis of the large body of scientific information ...
Breaking Biology News(10 mins):Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2Modeling tumor dormancy 2New report synthesizes best available science on management of moist mixed-conifer forests 2
(Date:10/22/2014)... , Oct. 22, 2014 New test ... the in vitro diagnostic (IVD) test industry, especially as ... healthcare market researcher listed more than 25 testing innovations ... be the future of IVD products. Kalorama details the new ... The Worldwide Market for In Vitro Diagnostic Tests ...
(Date:10/22/2014)... The North American crystal oscillator market report defines and ... forecast of revenue. This market was valued at $531.4 ... million by 2018, at a CAGR of 3.3% from ... the North American crystal oscillator market report, to get ... provides a glimpse of the segmentation of the market, ...
(Date:10/22/2014)... San Diego, CA (PRWEB) October 22, 2014 ... laboratory balances from Sartorius, A & D Weighing, ... Sartorius CPA Semi-Micro Balance . The Sartorius ... looking for an affordable high-quality, precise, and user-friendly ... in manufacturing of laboratory equipment, their laboratory balances ...
(Date:10/22/2014)... --  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... and diseases, announced today that the U.S. Patent and ... a composition of matter patent application that covers the ... This is Synthetic Biologics, first allowed patent application directly ... the Company,s extensive C. difficile patent estate. ...
Breaking Biology Technology:Report: Radical New IVD Test Approaches Key To Growth 2Report: Radical New IVD Test Approaches Key To Growth 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 2The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 4Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4
Cached News: